特应性皮炎发病机制及靶向药物治疗进展  

Advances in Pathogenesis and Targeted Drug Therapy of Atopic Dermatitis

作　　者：尹沫涵 马凌宇[1] 赵明 郑佳媛 张秀蕾 YIN Mohan;MA Lingyu;ZHAO Ming;ZHENG Jiayuan;ZHANG Xiulei(Department of Dermatology,Xi′an Gaoxin Hospital,Xi′an 710075,China)

机构地区：[1]西安高新医院皮肤科,西安710075

出　　处：《医学综述》2023年第16期3224-3228,3233,共6页Medical Recapitulate

摘　　要：特应性皮炎(AD)是慢性、反复发作性、炎症性皮肤病,皮损的主要临床特征是皮肤干燥,湿疹样皮疹,伴剧烈瘙痒。目前AD的病因尚不明确,多认为与遗传和微生物环境因素、免疫因素相关。长期以来,AD发病机制的相关研究主要集中在T细胞活化方面。随着免疫学的不断发展,发现角质形成细胞、辅助性T细胞(Th细胞)2、Th17细胞、Th22细胞等均参与了AD的发病,这为AD发病机制的研究提供了新的依据,也为AD的靶向治疗提供新的方向。Atopic dermatitis(AD)is a chronic,recurrent,inflammatory skin disease,and the main clinical feature of the lesions are dry,eczema-like skin rashes with intense itching.The etiology of AD is still unknown,and it′s mostly consi-dered to be related to genetic,microbial environmental factors,and immune factors.The pathogenesis study of AD has long been focused on T-cell activation.With the continuous development of immunology,keratinocytes,helper T cells(Th cells)2,Th17 cells and Th22 cells have been discovered to be involved in the pathogenesis of AD.These new findings provide a new basis for the pathogenesis study of AD and a new direction for the targeted treatment of AD.

关 键 词：特应性皮炎 发病机制 靶向治疗 

分 类 号：R758.2[医药卫生—皮肤病学与性病学]